Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease -: The final analysis of the arterial revascularization therapies study (ARTS) randomized trial

被引:451
作者
Serruys, PW
Ong, ATL
van Herwerden, LA
Sousa, JE
Jatene, A
Bonnier, JJRM
Schönberger, JPMA
Buller, N
Bonser, R
Disco, C
Backx, B
Hugenholtz, PG
Firth, BG
Unger, F
机构
[1] Erasmus Univ, Ctr Med, Thoraxctr, Intervent Cardiol Dept, NL-3015 GD Rotterdam, Netherlands
[2] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil
[3] Hosp Coracao, Sao Paulo, Brazil
[4] Catharina Hosp, Eindhoven, Netherlands
[5] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[6] Johnson & Johnson Co, Cordis, Warren, NJ USA
[7] Univ Klin Herzchirurg, Salzburg, Austria
关键词
D O I
10.1016/j.jacc.2004.12.082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The long-term (five-year) comparative results of treatment of multivessel coronary artery disease with stenting or coronary artery bypass grafting (CABG) is at present unknown. BACKGROUND The Arterial Revascularization Therapies Study, (ARTS) was designed to compare CABG and stenting in patients with multivessel disease. METHODS A total of 1,205 patients with the potential for equivalent revascularization were randomly assigned to CABG (n = 605) or stent implantation (n = 600). The primary clinical end point was freedom from major adverse cardiac and cerebrovascular events (MACCE) at one year; MACCE at five-year follow-up constituted the final secondary end point. RESULTS At five years, there were 48 and 46 deaths in the stent and CABG groups, respectively (8.0% vs. 7.6%; p = 0.83; relative risk [RR], 1.05; 95% confidence interval [CI], 0.71 to 1.55). Among 208 diabetic patients, mortality was 13.4% in the stent group and 8.3% in the CABG group (p = 0.27; RR, 1.61; 95% CI, 0.71 to 3.63). Overall freedom from death, stroke, or myocardial infarction was not significantly different between groups (18.2% in the stent group vs. 14.9% in the surgical group; p = 0.14; RR, 1.22; 95% CI, 0.95 to 1.58). The incidence of repeat revascularization was significantly higher in the stent group (30.3%) than in the CABG group (8.8%; p < 0.001; RR, 3.46;95% CI, 2.61 to 4.60). The composite event-free survival rate was 58.3% in the stent group and 78.2% in the CABG group (p < 0.0001; RR, 1.91;95% CI, 1.60 to 2.28). CONCLUSIONS At five years there was no difference in mortality between stenting and surgery for multivessel disease. Furthermore, the incidence of stroke or myocardial infarction was not significantly different between the two groups. However, overall MACCE was higher in the stent group, driven by the increased need for repeat revascularization. (c) 2005 by the American College of Cardiology Foundation
引用
收藏
页码:575 / 581
页数:7
相关论文
共 10 条
[1]  
[Anonymous], 1999, Int J Cardiovasc Intervent, V2, P41
[2]  
EAGLE KA, ACC AHA 2004 GUIDELI
[3]   A decade of change - Risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: A report from the STS National Database Committee and the Duke Clinical Research Institute [J].
Ferguson, TB ;
Hammill, BG ;
Peterson, ED ;
DeLong, ER ;
Grover, FL .
ANNALS OF THORACIC SURGERY, 2002, 73 (02) :480-489
[4]   ESTIMATION OF A COMMON EFFECT PARAMETER FROM SPARSE FOLLOW-UP DATA [J].
GREENLAND, S ;
ROBINS, JM .
BIOMETRICS, 1985, 41 (01) :55-68
[5]   A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: One- to eight-year outcomes [J].
Hoffman, SN ;
TenBrook, JA ;
Wolf, MP ;
Pauker, SG ;
Salem, DN ;
Wong, JB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) :1293-1304
[6]   Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J].
Moses, JW ;
Leon, MB ;
Popma, JJ ;
Fitzgerald, PJ ;
Holmes, DR ;
O'Shaughnessy, C ;
Caputo, RP ;
Kereiakes, DJ ;
Williams, DO ;
Teirstein, PS ;
Jaeger, JL ;
Kuntz, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14) :1315-1323
[7]   Argentine randomized study: Coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results [J].
Rodriguez, A ;
Bernardi, V ;
Navia, J ;
Baldi, J ;
Grinfeld, L ;
Martinez, J ;
Vogel, D ;
Grinfeld, R ;
Delacasa, A ;
Garrido, M ;
Oliveri, R ;
Mele, E ;
Palacios, I ;
O'Neill, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (01) :51-58
[8]   Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. [J].
Serruys, PW ;
Unger, F ;
Sousa, JE ;
Jatene, A ;
Bonnier, HJRM ;
Schonberger, JPAM ;
Buller, N ;
Bonser, R ;
van den Brand, MJB ;
van Herwerden, LA ;
Morel, MAM ;
van Hout, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (15) :1117-1124
[9]  
Sigwart U, 2002, LANCET, V360, P965
[10]   A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease [J].
Stone, GW ;
Ellis, SG ;
Cox, DA ;
Hermiller, J ;
O'Shaughnessy, C ;
Mann, JT ;
Turco, M ;
Caputo, R ;
Bergin, P ;
Greenberg, J ;
Popma, JJ ;
Russell, ME .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (03) :221-231